Pomalidomide has multiple mechanisms of action, including immune regulation, anti angiogenesis, and anti-tumor effects. It can inhibit the proliferation of hematopoietic tumor cells and induce their apoptosis through target brain mediation.

I. Drug name

1. Product Name: POMALYST

2. Common name: Pomalidomide

II. Indications

Used to treat multiple myeloma patients who have received at least two previous therapies (including lenalidomide and bortezomib) and have shown disease progression within 60 days after completion of the last therapy.

III. Specifications and characteristics

2mg, 4mg capsules

IV. Main components

Active ingredient: Pomalidomide

V. Usage and dosage

1. Recommended dosage: once daily, 4mg each time, orally, taken daily from day 1-21, every 28 days as a cycle, until disease progression.

2. Usage: The whole pill should be swallowed, and should not be opened, chewed, or crushed. It should be taken at least 2 hours before or 2 hours after eating.

VI. Dose adjustment

Adjust the dosage based on toxicity reactions: For patients with grade 3/4 hematological toxicity (such as neutropenia and thrombocytopenia), administration should be suspended until the toxicity is relieved, and then the dosage should be reduced according to the specific situation to restart treatment.

VII. Medication precautions

1. Before and after meals: take at least 2 hours before or 2 hours after eating.

2. Missed dose: If missed and more than 12 hours before the next dose, the missed dose should be skipped and the next dose should be taken according to the original plan.

3. Vomiting: If vomiting occurs after taking medication, it should not be repeated and the next dose should be taken according to the original schedule.

VIII. Medication for special populations

1. Pregnant women: contraindicated, pomalidomide has serious teratogenic effects on the fetus.

2. Breastfeeding women: The importance of medication to the mother and potential risks to the baby should be balanced before deciding whether to stop breastfeeding or medication.

3. Children: Safety and efficacy have not yet been established.

4. Elderly: No need to adjust dosage according to age.

5. Patients with renal impairment: Patients with serum creatinine>3.0mg/dL should avoid using it.

6. Patients with liver function impairment: Patients with serum bilirubin>2.0mg/dL and AST/ALT>3.0xULN should avoid using it.

7. Male patients: During treatment and within 28 days after discontinuation of medication, latex or synthetic condoms should be used for sexual intercourse with women of childbearing age, and sperm donation is not allowed.

IX. Adverse reactions

1. The most common adverse reactions (≥ 30%) include fatigue and weakness, neutropenia, anemia, constipation, nausea, diarrhea, difficulty breathing, upper respiratory tract infections, back pain, and fever.

2. Other serious adverse reactions include: venous thromboembolism, hematological toxicity, hypersensitivity reactions, dizziness and confusion, neuropathy, secondary primary malignant tumors, etc.

X. Contraindications

1. Pregnant women are prohibited from using it.

2. Patients allergic to pomalidomide or any of its components are prohibited from using it.

XI. Drug interactions

1. CYP3A, CYP1A2, or P-gp inhibitors: may increase plasma concentrations of pomalidomide and should be avoided in combination.

2. CYP3A, CYP1A2, or P-gp inducers: may reduce plasma concentrations of pomalidomide and should be avoided in combination.

3. Smoking: May reduce the plasma concentration of pomalidomide, as smoking may induce CYP1A2.

XII. Storage method

Stored in an environment of 20 ° C-25 ° C (68 ° F-77 ° F), with an allowable range of 15 ° C-30 ° C (59 ° F-86 ° F).

Pomalidomideinformation